Performance evaluation of an in-house human immunodeficiency virus type-1 protease-reverse transcriptase genotyping assay in Cameroon

被引：43

作者：

Fokam, J. ^{[2
,3
]}

Salpini, R. ^{[1
]}

Santoro, M. M. ^{[1
]}

Cento, V. ^{[1
]}

D'Arrigo, R. ^{[4
]}

Gori, C. ^{[4
]}

Perno, C. F. ^{[1
,4
]}

Colizzi, V. ^{[1
,2
]}

Nanfack, A. ^{[2
]}

Gwom, L. C. ^{[2
,3
]}

Cappelli, G. ^{[2
,5
]}

Takou, D. ^{[2
]}

机构：

[1] Univ Roma Tor Vergata, Dept Expt Med & Biochem Sci, I-00133 Rome, Italy

[2] CIRCB Chantal BIYA Int Res Ctr Res HIV AIDS Prev, Yaounde, Cameroon

[3] Univ Yaounde, Fac Med & Biomed Sci, Yaounde, Cameroon

[4] IRCSS L Spallanzani, Rome, Italy

[5] CNR, Rome, Italy

来源：

ARCHIVES OF VIROLOGY | 2011年 / 156卷 / 07期

关键词：

ANTIRETROVIRAL DRUG-RESISTANCE; HIV GENETIC DIVERSITY; SYSTEM; INFECTION; SURVEILLANCE; DIAGNOSIS; THERAPY; IMPACT;

D O I：

10.1007/s00705-011-0982-3

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

Most commercial HIV-1 genotyping assays are hampered by high cost in resource-limited settings. Moreover, their performance might be influenced over time by HIV genetic heterogeneity and evolution. An in-house genotyping protocol was developed, and its sequencing performance and reproducibility were compared to that of ViroSeq (TM). One hundred ninety plasma samples from HIV-1-infected subjects in Cameroon, a resource-limited setting with a high HIV genetic variability, were processed for pol gene sequencing with an in-house protocol, ViroSeq (TM), or both. Only non-B subtypes were found. The in-house sequencing performance was 98.7% against 92.1% with ViroSeq (TM). Among 36 sequence pairs obtained using both assays, the overall rate of discordant amino acid positions was negligible (0.24%). With its high sensitivity and reproducibility, as well as its affordable cost (about half of ViroSeq (TM): 92 a,not sign vs. 217 a,not sign), this in-house assay is a suitable alternative for HIV-1 genotyping in resource-limited and/or in high-genetic-diversity settings.

引用

页码：1235 / 1243

页数：9

共 46 条

[1]

[Anonymous], 2009, Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents, P1

[2]

[Anonymous], 2002, PAUP*. Phylogenetic Analysis Using Parsimony (*and other methods). Version 4

[3]

[Anonymous], 2006, ANT THER HIV INF AD

[4] The requirement for surveillance of HIV drug resistance within antiretroviral rollout in the developing world [J].

Bennett, Diane E. .

CURRENT OPINION IN INFECTIOUS DISEASES, 2006, 19 (06) :607-614

[5] Drug Resistance Mutations for Surveillance of Transmitted HIV-1 Drug-Resistance: 2009 Update [J].

Bennett, Diane E. ;

Camacho, Ricardo J. ;

Otelea, Dan ;

Kuritzkes, Daniel R. ;

Fleury, Herve ;

Kiuchi, Mark ;

Heneine, Walid ;

Kantor, Rami ;

Jordan, Michael R. ;

Schapiro, Jonathan M. ;

Vandamme, Anne-Mieke ;

Sandstrom, Paul ;

Boucher, Charles A. B. ;

van de Vijver, David ;

Rhee, Soo-Yon ;

Liu, Tommy F. ;

Pillay, Deenan ;

Shafer, Robert W. .

PLOS ONE, 2009, 4 (03)

[6] Scaling up access to antiretroviral treatment for HIV infection: the impact of decentralization of healthcare delivery in Cameroon [J].

Boyer, Sylvie ;

Eboko, Fred ;

Camara, Mamadou ;

Abe, Claude ;

Nguini, Mathias Eric Owona ;

Koulla-Shiro, Sinata ;

Moatti, Jean-Paul .

AIDS, 2010, 24 :S5-S15

[7]

Braitstein P, 2006, LANCET, V367, P817, DOI 10.1016/S0140-6736(06)68337-2

[8] HIV genetic diversity: Biological and public health consequences [J].

Butler, Isolde F. ;

Pandrea, Ivona ;

Marx, Preston A. ;

Apetrei, Cristian .

CURRENT HIV RESEARCH, 2007, 5 (01) :23-45

[9]

Clavel F, 2004, NEW ENGL J MED, V350, P1023, DOI 10.1056/NEJM2ra025195

[10]

*COM NAT LUTT SIDA, MIN SANT PUBL CAM JU

← 1 2 3 4 5 →